StockIQpro
NYSE:DNA

Ginkgo Bioworks Holdings, Inc.

Track all markets on TradingView
Track all markets on TradingView

Ginkgo Bioworks Holdings, Inc.'s revenue fell 25.1% in fiscal 2025 to $170.2M while operating margin rose to −185.3%. Free cash flow was −$178.7M, −105.0% of revenue, and the diluted share count rose 6.9%.Summary generated from Ginkgo Bioworks Holdings, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$170.2M
Revenue growth−25.1%
Revenue, 5-yr CAGR+17.3%
Gross marginn/a
Operating margin−185.3%
Net margin−183.8%
ROICn/a
Return on equity−51.1%
Debt / equityn/a
Free cash flow−$178.7M
FCF margin−105.0%
Share count change+6.9%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue314478251227170
Operating income−1,828−2,209−864−560−315
Net income−1,830−2,105−893−547−313
Free cash flow−310−304−336−382−179

Recent filings

From SEC EDGAR

Peers

Biological products, (no diagnostic substances)